Related Experiment Video
Updated: Jun 25, 2026
10:26
A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Biomarkers and venous thromboembolism
1Clinical Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. ingrid.pabinger@meduniwien.ac.at
Arteriosclerosis, Thrombosis, and Vascular Biology
|February 21, 2009
Summary
Identifying biomarkers for venous thromboembolism (VTE) risk is crucial. This review discusses D-dimer, P-selectin, factor VIII, inflammatory markers, and thrombin generation for predicting VTE.
Area of Science:
- Biochemistry
- Hematology
- Clinical Medicine
Background:
- Venous thromboembolism (VTE) poses significant health risks due to high morbidity, mortality, and recurrence rates.
- Early identification of patients at high or low risk for primary and recurrent VTE is clinically important.
- Biomarkers are needed to aid in VTE diagnosis, risk stratification, and management.
Purpose of the Study:
- To review established and novel biomarkers for predicting primary and recurrent VTE.
- To discuss the clinical application of biomarkers reflecting a prothrombotic state.
- To summarize data on specific biomarkers including D-dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers, and thrombin generation.
Main Methods:
- Literature review of studies investigating biomarkers for VTE.
- Analysis of data on biomarkers with procoagulant properties or that indicate a prothrombotic state.
- Discussion of the role of selected biomarkers in clinical practice.
Main Results:
- Selected biomarkers such as D-dimer, soluble P-selectin, coagulation factor VIII, inflammatory markers, and thrombin generation have been investigated for VTE prediction.
- These biomarkers reflect procoagulant properties or a prothrombotic state.
- Their potential roles in diagnosis, risk stratification, and management are under evaluation.
Conclusions:
- Biomarkers hold promise for improving the early identification of patients at risk for VTE.
- Further research and clinical validation are necessary to optimize the use of these biomarkers in VTE management.
- Understanding biomarker roles can enhance clinical decision-making for VTE patients.
Related Concept Videos
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...